Table 1.
Baseline characteristics of study population.
| Variable | Nonrecurrent group (n=193) | Recurrent group (n=70) | P value |
|---|---|---|---|
| Female [n (%)] | 77 (40) | 33 (47) | 0.292 |
| Age (year) | 62 (53, 69) | 62 (57, 67) | 0.694 |
| Course of disease (months) | 24.0 (3.0, 54.5) | 24.0 (6.0, 48.0) | 0.513 |
| BMI (kg/m2) | 25.31±3.30 | 25.22±2.75 | 0.839 |
| Hypertension | 123 (64) | 43 (61) | 0.732 |
| Diabetes mellitus | 24 (12) | 10 (14) | 0.693 |
| Cerebral infarction | 11 (6) | 5 (7) | 0.888 |
| Smoking | 33 (17) | 9 (13) | 0.407 |
| Alcohol | 22 (11) | 8 (11) | 0.995 |
| CHA2DS2-VASc score | 0.469 | ||
| 0 | 30 (16) | 12 (17) | |
| 1 | 47 (24) | 18 (26) | |
| 2 | 57 (30) | 14 (20) | |
| ≥3 | 59 (30) | 26 (37) | |
| AF type | 0.002* | ||
| Paroxysmal AF | 153 (79) | 42 (60) | |
| Persistent AF | 40 (21) | 28 (40) | |
| Previous medication | |||
| ACEI/ARB | 62 (32) | 19 (27) | 0.439 |
| β-blockers | 92 (48) | 33 (47) | 0.940 |
| CCB | 67 (35) | 20 (29) | 0.349 |
| Amiodarone | 33 (17) | 9 (13) | 0.407 |
| Propafenone | 17 (9) | 6 (9) | 0.952 0.809 |
| Preoperative anticoagulants | |||
| Low molecular heparin | 126 (66) | 48 (69) | |
| Warfarin | 33 (17) | 12 (17) | |
| NOAC | 34 (17) | 10 (14) |
ACEI – angiotensin-converting enzyme inhibitor; ARBs – AT1 blockers; BMI – body mass index; CCB – calcium channel blockers.
*
P<0.01.